menu
    • menu
    [{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Partnership","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"INAF","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ INAF","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ INAF"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"TP ICAP Midcap","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"TOTUM\u2022070","moa":"Lipid metabolism","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ TP ICAP Midcap","highestDevelopmentStatusID":"8","companyTruncated":"Valbiotis \/ TP ICAP Midcap"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Inapplicable"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ University of Avignon"},{"orgOrder":0,"company":"Valbiotis","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"TOTUM\u202263","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Valbiotis \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Valbiotis","sponsor":"University of Avignon","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"TOTUM\u2022854","moa":"NOS","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III","graph3":"Valbiotis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valbiotis \/ University of Avignon","highestDevelopmentStatusID":"9","companyTruncated":"Valbiotis \/ University of Avignon"}]

    Find Clinical Drug Pipeline Developments & Deals by Valbiotis

    Menu

    Valbiotis

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study...

                            Details : TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes. TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets.

                            Product Name : TOTUM•63

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            May 22, 2023

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Nestle Health Sciences SA

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM•854 Clinical Study, Aga...

                            Details : TOTUM•854, a patented active substance based on a combination of plant extracts, is developed to reduce blood pressure in people with mild to moderate hypertension, by reducing angiotensin I-converting enzyme (ACE1) activity.

                            Product Name : TOTUM•854

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            January 30, 2023

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : TP ICAP Midcap

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Valbiotis Successfully Completes a Fundraise of 9.7 Million Euros

                            Details : TOTUM•070 is a combination of plant extracts, with no phytosterol or red yeast rice content. TOTUM•070 is being developed with a view to obtaining a proprietary health claim relating to the reduction of blood LDL cholesterol, a risk factor for cardio...

                            Product Name : Totum•070

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Undisclosed

                            September 11, 2022

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : TP ICAP Midcap

                            Deal Size : $10.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : INAF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces the First Visit of the First Patient in the TOTUM•63 Mode of Action Clinical Study Condu...

                            Details : TOTUM-63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes, has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study.

                            Product Name : TOTUM•63

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            April 29, 2022

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : INAF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TO...

                            Details : This innovative study is the first to characterize the metabolites of TOTUM•070 in humans and their mode of action in the liver in a population of 10 healthy volunteers. TOTUM•070 was tested at its clinical daily dose (5g), used also in the Phase II ...

                            Product Name : Totum•070

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            March 29, 2022

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : University of Avignon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Reveals Positive TOTUM•854 Preclinical Results in the Prevention of Hypertension at the Annual ESH...

                            Details : The results, obtained in vivo on models predictive of hypertension in humans, showed that TOTUM•854 is effective in preventing hypertension.

                            Product Name : TOTUM•854

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            December 04, 2021

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : University of Avignon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : University of Avignon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VALBIOTIS Selected to Present TOTUM-854’s Results

                            Details : Preclinical results with the active substance TOTUM-854 on arterial hypertension, obtained through work undertaken as part of an academic partnership with Avignon University’s Laboratoire de Pharm-Ecologie Cardiovasculaire (LAPEC) as well as at the Rio...

                            Product Name : TOTUM•854

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            August 03, 2021

                            Lead Product(s) : TOTUM•854

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : University of Avignon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Valbiotis Authorized to Launch HEART for TOTUM-070 to treat High Blood LDL-Cholesterol Levels

                            Details : The main objective of this clinical study is to evaluate the efficacy of a 5g daily dose of TOTUM-070 and to confirm its safety. HEART results will support the application for a proprietary health claim related to the reduction of LDL-cholesterol.

                            Product Name : Totum•070

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 15, 2021

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, Starts Phase II ...

                            Details : The clinical study HEART on TOTUM-070, a Phase II randomized placebo-controlled and double blind study, has just been initiated in accordance with the road map, the study protocol having been submitted to the French health authorities.

                            Product Name : Totum•070

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : TOTUM•070

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed

                            Valbiotis

                            France arrow
                            Pharma Live Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VALBIOTIS Selected to Present 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes (EAS...

                            Details : EASD has selected the positive results of the international Phase II clinical study on TOTUM-63 in prediabetes to be presented next September in its 56th annual meeting. These results were selected by the American Diabetes Association last June 2020.

                            Product Name : TOTUM•63

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            September 21, 2020

                            Lead Product(s) : TOTUM•63

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth